A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Metastatic Colorectal Cancer (mCRC)

Study type: Observational

Funder types: Industry

Identifiers

NCT05420909

CA209-7AU

Details and patient eligibility

About

The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.

Enrollment: 124 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by:
• Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x)
• Pathology consistent with CRC
• At least two documented clinical visits on or after January 1, 2013
• Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013
• Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR)
• Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date
• Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study

Exclusion criteria

• Participants <18 years of age at index date
• Participants who received clinical trial drug during the prior or post periods

Trial design

124 participants in 1 patient group

Cohort 1

Description:

Participants diagnosed with metastatic colorectal cancer (mCRC) selected from the Flatiron Electronic Health Record database